Product
Ralinepag
Aliases
APD811
4 clinical trials
13 indications
Indication
Healthy VolunteerIndication
Pharmacokinetic StudyIndication
Pulmonary Arterial HypertensionIndication
Pulmonary HypertensionIndication
HypertensionIndication
Connective Tissue DiseasesIndication
Primary Pulmonary HypertensionIndication
Vascular DiseasesIndication
Cardiovascular DiseasesIndication
PulmonaryIndication
Lung DiseasesIndication
Respiratory Tract DiseaseIndication
Connective Tissue DiseaseClinical trial
A Phase 1 Open-label, Non-randomized, Single Ascending Dose Escalation Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of A Ralinepag Extended Release (XR) Tablet Formulation In Healthy Chinese SubjectsStatus: Completed, Estimated PCD: 2020-11-09
Clinical trial
A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepag in Subjects With World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH)Status: , Estimated PCD: 2024-09-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated TherapyStatus: Terminated, Estimated PCD: 2023-04-12
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAHStatus: Recruiting, Estimated PCD: 2024-12-01